Hofseth BioCare ASA (HOFBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hofseth BioCare ASA (HOFBF) trades at $0.17 with AI Score 43/100 (Grade C). Hofseth BioCare ASA specializes in biomarine ingredients for health applications, focusing on innovative products derived from salmon. Market cap: $65.82M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for HOFBF: HOFBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HOFBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HOFBF: the 1 perspectives are evenly split.
How is this calculated? →Hofseth BioCare ASA (HOFBF) Healthcare & Pipeline Overview
Hofseth BioCare ASA is a biotechnology company that develops high-value biomarine ingredients from salmon, catering to health and wellness markets for both humans and animals, with a focus on innovative and research-backed products.
What Is the Investment Thesis for HOFBF?
Hofseth BioCare ASA presents a unique investment thesis driven by its innovative product range and strategic partnerships. The company’s market capitalization stands at $0.07 billion, reflecting its potential for growth in the biomarine ingredient sector. With a gross margin of 37.2%, Hofseth BioCare is positioned to improve profitability as it scales operations and expands its market presence. The ongoing research collaboration with Stanford University could lead to significant advancements in product efficacy and new market opportunities, particularly in the healthcare space. As the global demand for natural and health-oriented products continues to rise, Hofseth BioCare is well-positioned to capitalize on these trends. However, investors should remain cognizant of the company’s current profit margin of -52.6%, indicating operational challenges that need to be addressed for sustainable growth.
Based on FMP financials and quantitative analysis
HOFBF Key Highlights
- Market capitalization of $65.82M indicates potential for growth in the biomarine sector.
- Gross margin of 37.2% reflects competitive pricing and cost management strategies.
- Research agreement with Stanford University enhances product credibility and market potential.
- Diverse product portfolio targeting both human and animal health markets.
- Beta of 0.41 suggests lower volatility compared to the market.
Who Are HOFBF's Competitors?
HOFBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NUTR NUSATRIP Inc | $41.80 | +0.00% | $628.33M | 59 |
| COLL Collegium Pharmaceutical, Inc. | $38.02 | +2.67% | $1.23B | 89 |
| ELAN Elanco Animal Health Incorporated | $25.16 | +0.64% | $12.57B | 33 |
| AVID Avid Technology, Inc. | $27.05 | +0.02% | $1.19B | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HOFBF's Key Strengths?
- Innovative product range with a focus on biomarine ingredients.
- Strong research partnerships enhance product development.
- Established brand presence in the health and wellness market.
- Diverse product offerings cater to both human and animal health.
What Are HOFBF's Weaknesses?
- Negative profit margin indicating operational challenges.
- Limited market capitalization may restrict growth initiatives.
- Dependence on specific product lines for revenue generation.
- Relatively small employee base may limit operational capacity.
What Could Drive HOFBF Stock Higher?
- Launch of new product lines targeting emerging health trends.
- Research collaboration with Stanford University for innovative health solutions.
- Expansion into new geographical markets to increase sales reach.
- Development of marketing strategies to enhance brand visibility.
- Potential partnerships with healthcare providers for product validation.
What Are the Key Risks for HOFBF?
- Financial-distress signal — its Altman Z-Score of -0.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges affecting product claims and market entry.
- Competitive pressures from established players in the biotechnology sector.
- Supply chain disruptions impacting ingredient availability.
- Market volatility affecting consumer spending on health products.
What Are the Growth Opportunities for HOFBF?
- Growth opportunity 1: The global dietary supplements market is projected to reach $230 billion by 2027, growing at a CAGR of 8.2%. Hofseth BioCare's innovative salmon oil products are well-positioned to capture a share of this expanding market, particularly as consumers increasingly prioritize health and wellness. The company's focus on high-quality, research-backed ingredients can differentiate it from competitors.
- Growth opportunity 2: The collagen market is expected to exceed $6 billion by 2025, driven by rising consumer interest in beauty and anti-aging products. Hofseth BioCare's CollaGo collagen peptide powder offers a unique value proposition, targeting this lucrative segment. The company's commitment to quality and efficacy can enhance its market penetration in the collagen space.
- Growth opportunity 3: With the increasing prevalence of digestive disorders, the demand for functional foods is on the rise. Hofseth BioCare's research collaboration with Stanford University could lead to new product developments targeting conditions like irritable bowel syndrome, opening up additional revenue streams and enhancing brand reputation.
- Growth opportunity 4: The pet supplement market is anticipated to grow to $1.7 billion by 2027, as pet owners seek high-quality nutritional products for their animals. Hofseth BioCare's PetGo non-soluble protein product can tap into this growing trend, leveraging the company's expertise in biomarine ingredients to offer premium solutions for pet health.
- Growth opportunity 5: As sustainability becomes a critical factor in consumer purchasing decisions, Hofseth BioCare's focus on biomarine ingredients aligns with the growing trend towards environmentally friendly products. The company's sustainable sourcing and production practices can enhance its appeal to eco-conscious consumers, driving growth.
What Opportunities Does HOFBF Have?
- Growing global demand for dietary supplements and functional foods.
- Expansion into emerging markets with rising health awareness.
- Potential for new product development through research collaborations.
- Increasing consumer preference for sustainable and natural products.
What Threats Does HOFBF Face?
- Intense competition in the biotechnology and health supplement sectors.
- Regulatory challenges related to product claims and safety.
- Market volatility impacting consumer spending on health products.
- Potential supply chain disruptions affecting ingredient sourcing.
What Are HOFBF's Competitive Advantages?
- Strong research collaborations with reputable institutions enhance product credibility.
- Unique product formulations derived from salmon provide a competitive edge.
- Commitment to sustainability and quality differentiates Hofseth in the market.
- Established distribution networks facilitate broad market access.
- Focus on innovation and continuous product development keeps offerings relevant.
What Does HOFBF Do?
Founded in 2000 and headquartered in Ålesund, Norway, Hofseth BioCare ASA has established itself as a key player in the biotechnology sector, specializing in biomarine ingredients. The company was created with the vision of harnessing the nutritional benefits of salmon, utilizing its unique properties to develop products that promote health and wellness. Over the years, Hofseth BioCare has evolved its product offerings to include a variety of innovative solutions such as Brilliant salmon oil, OmeGo salmon oil, ProGo salmon protein hydrolysate, CalGo marine calcium powder, CollaGo collagen peptide powder, and PetGo non-soluble protein. These products are designed to support various health functions, including cardiovascular health, joint support, and beauty enhancement. The company distributes its products through a network of distributors, agents, and its own sales force, ensuring a broad market reach both domestically and internationally. Additionally, Hofseth BioCare has entered into a research agreement with Stanford University School of Medicine, focusing on pre-clinical and clinical research for conditions such as necrotizing enterocolitis and irritable bowel syndrome. This collaboration underscores the company’s commitment to scientific validation and innovation in its product development.
What Products and Services Does HOFBF Offer?
- Develops high-value biomarine ingredients from salmon for health applications.
- Offers a range of products targeting human health, including omega oils and protein supplements.
- Produces specialized products for animal health and nutrition.
- Engages in research collaborations to validate product efficacy and explore new applications.
- Distributes products through a network of agents, distributors, and direct sales.
- Focuses on innovation and quality in product development to meet market demands.
How Does HOFBF Make Money?
- Generates revenue through the sale of biomarine health products for humans and animals.
- Utilizes a combination of direct sales and distribution partnerships to reach a broad customer base.
- Engages in research collaborations to enhance product offerings and market credibility.
- Focuses on premium pricing strategies to reflect product quality and efficacy.
- Invests in marketing and brand development to build recognition in the health and wellness sector.
What Industry Does HOFBF Operate In?
The biotechnology industry is experiencing robust growth, driven by increasing consumer demand for health and wellness products. The biomarine ingredients segment, in particular, is gaining traction as consumers seek natural alternatives for health supplements and functional foods. Hofseth BioCare ASA operates within this expanding market, leveraging its expertise in salmon-derived products to meet the rising demand. Competitive pressures are evident, with several players focusing on similar health-oriented products, but Hofseth's unique offerings and research collaborations position it favorably within the industry landscape.
Who Are HOFBF's Key Customers?
- Health-conscious consumers seeking natural dietary supplements.
- Athletes and fitness enthusiasts looking for high-quality protein sources.
- Pet owners interested in premium nutritional products for their animals.
- Healthcare professionals and researchers involved in nutrition and wellness.
- Distributors and retailers specializing in health and wellness products.
How Hofseth BioCare ASA Is Valued
Hofseth BioCare ASA carries a market capitalization of $65.82M, placing it in the micro-cap category. Relative to its peer group, HOFBF's quantitative score of 43/100 is below the peer average of 62/100.
Company Profile
Hofseth BioCare ASA operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ålesund, NO. The company is led by CEO Jon Olav Odegard. HOFBF has traded publicly since 2018.
Key Financial Metrics
Return on assets is -34.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.67 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -23.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Hofseth BioCare ASA's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.39 places it in the distress zone, a signal of elevated financial risk.
HOFBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in Hofseth BioCare's growth potential, indicating that those closest to the company believe in its future.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative approach to sustainable aquaculture.
- The growing demand for plant-based and omega-3 products aligns well with Hofseth's offerings, positioning them favorably in a lucrative market.
- Recent partnerships and collaborations have garnered attention, suggesting that the company is expanding its market reach and enhancing its product portfolio.
Bear Case
- Concerns have been raised about the competitive landscape in the aquaculture industry, with several players vying for market share.
- Some community members express skepticism regarding the scalability of Hofseth's operations, questioning whether they can meet rising demand effectively.
- Recent regulatory challenges in the food sector have created uncertainty, potentially impacting Hofseth's operational efficiency and market entry strategies.
- Market perception remains cautious, as investors are wary of the company's ability to deliver consistent growth amid fluctuating demand trends.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
HOFBF Latest News
-
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2026
globenewswire.com · Jun 9, 2026
-
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M
globenewswire.com · May 21, 2026
HOFBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HOFBF.
Price Targets
Wall Street price target analysis for HOFBF.
HOFBF MoonshotScore
What does this score mean?
The MoonshotScore rates HOFBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jon Olav Odegard
CEO
Jon Olav Odegard has been at the helm of Hofseth BioCare ASA since its inception in 2000. With a background in business management and extensive experience in the biotechnology sector, he has played a pivotal role in shaping the company’s strategic direction. His leadership has been instrumental in establishing Hofseth as a recognized name in biomarine ingredients, driving innovation and product development.
Track Record: Under Jon Olav Odegard's leadership, Hofseth BioCare has successfully launched a range of innovative products and established key research partnerships, including a significant collaboration with Stanford University. His focus on quality and sustainability has positioned the company favorably within the competitive landscape.
HOFBF OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like NYSE or NASDAQ, often characterized by lower trading volumes and less stringent reporting requirements. This tier can present unique opportunities and risks for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower regulatory oversight compared to major exchanges may increase investment risks.
- Potential for higher volatility and price fluctuations in OTC markets.
- Limited availability of financial information can hinder informed investment decisions.
- Smaller market capitalization may lead to liquidity issues.
- Verify the company's financial health and operational performance.
- Research the competitive landscape and market positioning.
- Review the management team's background and track record.
- Assess the company's product pipeline and research collaborations.
- Understand the regulatory environment affecting the biotechnology sector.
- Established partnerships with reputable institutions like Stanford University.
- A diverse product portfolio targeting both human and animal health.
- Transparency in product sourcing and sustainability practices.
Hofseth BioCare ASA Healthcare Stock: Key Questions Answered
What does Hofseth BioCare ASA do?
Hofseth BioCare ASA specializes in developing high-value biomarine ingredients derived from salmon for both human and animal health applications. The company offers a diverse range of products, including omega oils, protein supplements, and collagen peptides, aimed at promoting wellness and addressing specific health needs.
What do analysts say about HOFBF stock?
Analysts generally view Hofseth BioCare ASA as a company with potential for growth, particularly due to its innovative product offerings and research collaborations. Key valuation metrics, such as market capitalization and gross margin, indicate areas for improvement, while the ongoing development of its product pipeline is a focal point for future growth.
What are the main risks for HOFBF?
Hofseth BioCare ASA faces several risks, including regulatory challenges that could impact product claims and market access. Additionally, the company operates in a competitive biotechnology landscape, which may pressure pricing and market share. Supply chain disruptions and market volatility also pose potential threats to its operational stability.
What are the key factors to evaluate for HOFBF?
Hofseth BioCare ASA (HOFBF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does HOFBF data refresh on this page?
HOFBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HOFBF's recent stock price performance?
Hofseth BioCare ASA (HOFBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product range with a focus on biomarine ingredients. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HOFBF overvalued or undervalued right now?
Valuing Hofseth BioCare ASA (HOFBF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HOFBF?
Before investing in Hofseth BioCare ASA (HOFBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial reports and disclosures are limited due to OTC classification.